在干眼疾病中,SIRT1通过增强HIF1α蛋白稳定性来预防角膜上皮细胞中的铁亡
Lili Lian1, Zhenmin Le2, Xuanqiao Ye1
1Eye Hospital and School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|February 25, 2026
概括
干眼疾病涉及角膜细胞的氧化损伤和铁亡. 这项研究揭示了激活sirtuin 1 (SIRT1) 抑制铁,为干眼疾病提供了潜在的治疗策略.
科学领域:
- 眼科医生 眼科 眼科
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 干眼病 (DED) 的发病包括由于膜不稳定导致的角膜上皮细胞的氧化损伤.
- 铁,一种依赖于铁的细胞死亡形式,是DED氧化损伤的关键机制,但其调节不清楚.
研究的目的:
- 为了阐明角膜上皮细胞中铁亡的调节机制,在高度应激下.
- 调查NAD依赖性脱乙酶Sirtuin 1 (SIRT1) 在DED期间铁亡中的作用.
- 探索SIRT1激活作为DED治疗策略的潜力.
主要方法:
- 在透性应激下使用角膜上皮细胞的体外和体内模型.
- 研究了超体应激对SIRT1表达和活性的影响.
- 研究了SIRT1,GPX4和HIF1α之间的监管关系.
- 评估了使用SRT1720.20的药理SIRT1激活的治疗潜力.
主要成果:
- 超的压力降低SIRT1的调节,促进角膜上皮细胞中的铁亡.
- SIRT1积极调节GPX4,这是一个关键的铁灭抑制剂.
- SIRT1去乙化和稳定HIF1α,增强GPX4水平并抑制铁亡.
- 通过SRT1720介导的SIRT1激活减少了角膜上皮细胞中的氧化损伤和铁亡.
结论:
- 已经确定了一种新的SIRT1-HIF1α通路,可以调节DED中的铁亡.
- 激活SIRT1代表了一种有前途的治疗方法,以减轻角膜中的氧化损伤和铁亡.
- 准这种途径可能为干眼疾病提供新的治疗方法.
相关概念视频
01:22iPS Cell Differentiation
3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K
01:31Regulation of the Unfolded Protein Response
3.1K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K